glp-1 agonists for type 2 diabetes GLP1 Receptor vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog A clinician's perspective 📝 GLP-1

Lassen, M

Open 3 , e2027421 (2020)

These medications have been shown to not only support weight loss but also help manage blood sugar levels, addressing two common struggles that often feel impossible to tackle simultaneously

Acute Kidney Injury: Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe

in addition, one was due to an intrauterine cytomegalovirus infection associated with anomalies, one genetic anomaly

Medicare GLP-1 Bridge program Beginning July 1, 2026 through December 31, 2027, eligible Medicare beneficiaries can access the following FDA-approved GLP-1 medications for weight loss : Wegovy (injection or tablet), Foundayo (tablet), and Zepbound (KwikPen only) for $50/month *** through the Medicare GLP-1 Bridge program